Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy

About this update from Abeona Therapeutics Inc.

[{"type":"text","content":"CLEVELAND, Ohio and AURORA, Colo., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) and Children's Hospital Colorado today announced activation of Children's Colorado as the newest Qualified Treatment Center (QTC) for ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. This first-of-its-kind therapy is FDA-approved to treat wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). Children's Colorado in Aurora, CO, one of the pioneering institutions that provide advanced levels of care for people with epidermolysis bullosa (EB), has completed QTC start-up activities enabling it to begin patient identification for scheduling of ZEVASKYN treatment. Anna L. Bruckner, MD, Co-Director of the EB Clinic at Children’s Hospital of Colorado and Professor of Dermatology, University of Colorado School of Medicine, said, “We are thrilled to be able to provide our patients a much needed, long lasting treatment option, and with it, the hope for an improved quality of life.” “We are excited to be working with Dr. Bruckner and Children's Hospital Colorado in making ZEVASKYN available to RDEB patients,” said Dr. Madhav Vasanthavada, Chief Commercial Officer of Abeona. “Dr. Bruckner is one of the leading experts in EB care, and the activation of Children’s Colorado is a major milestone in broadening access to ZEVASKYN across a growing network of established EB centers.” Children’s Hospital Colorado’s epidermolysis bullosa program is recognized as a center of excellence by debra of America, the lead patient advocacy organization for EB. Children's Colorado is a member of the EB Clinical Research Consortium and continues to conduct cutting-edge bench and clinical research to reshape the future of rare disease treatment and offer significant promise of transformative care and better quality of life for patients with EB. The Precision Medicine Institute at Children’s Colorado supports these programs through pioneering novel treatments like this, using each patient’s unique genetic information to treat their disease. For more information on how to access ZEVASKYN and learn about patient support services offered through Abeona Assist™, Abeona’s comprehensive patient support program, visit www.abeonaassist.com, call 1-855-ABEONA-1 (1-855-223-6621) or email MyNavigator@AbeonaAssis...

More updates from Abeona Therapeutics Inc.